Literature DB >> 8822237

Effect of losartan on right ventricular hypertrophy and cardiac angiotensin I-converting enzyme activity in pulmonary hypertensive rats.

R Kreutz1, M S Fernandez-Alfonso, D Ganten, M Paul.   

Abstract

The aim of this study was to investigate the effect of prophylactic treatment with the angiotensin type 1 (AT1) receptor antagonist losartan on right ventricular hypertrophy and cardiac angiotensin 1-converting enzyme (ACE) activity in a rat model of monocrotaline-induced pulmonary hypertension. Losartan failed to prevent either pulmonary hypertension or right ventricular hypertrophy. Right ventricular ACE in untreated pulmonary hypertensive rats did not differ from control rats. Losartan treatment in pulmonary hypertensive rats caused a significant 2-fold increase of ACE activity in the hypertrophied right (p < 0.005) but not in the left ventricle. Thus, cardiac ACE activity is not stimulated in rats with monocrotaline-induced right ventricular hypertrophy. Prophylactic losartan treatment in this model of progressive pulmonary hypertension failed to prevent or reduce the increase in ventricular afterload. The relevance of the increase in right ventricular ACE activity during pulmonary hypertension after losartan treatment is unknown and needs to be evaluated in further studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8822237     DOI: 10.3109/10641969609082610

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  4 in total

1.  The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension.

Authors:  Vinayak Shenoy; Anderson J Ferreira; Yanfei Qi; Rodrigo A Fraga-Silva; Carlos Díez-Freire; Autumn Dooies; Joo Yun Jun; Srinivas Sriramula; Nithya Mariappan; Dorna Pourang; Changaram S Venugopal; Joseph Francis; Timothy Reudelhuber; Robson A Santos; Jawaharlal M Patel; Mohan K Raizada; Michael J Katovich
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

Review 2.  ACE2, a promising therapeutic target for pulmonary hypertension.

Authors:  Vinayak Shenoy; Yanfei Qi; Michael J Katovich; Mohan K Raizada
Journal:  Curr Opin Pharmacol       Date:  2011-01-05       Impact factor: 5.547

Review 3.  Autonomic nervous system involvement in pulmonary arterial hypertension.

Authors:  Mylène Vaillancourt; Pamela Chia; Shervin Sarji; Jason Nguyen; Nir Hoftman; Gregoire Ruffenach; Mansoureh Eghbali; Aman Mahajan; Soban Umar
Journal:  Respir Res       Date:  2017-12-04

Review 4.  Neurohormonal Modulation as a Therapeutic Target in Pulmonary Hypertension.

Authors:  Inés García-Lunar; Daniel Pereda; Borja Ibanez; Ana García-Álvarez
Journal:  Cells       Date:  2020-11-22       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.